Drug Approved by FDA for Pancreatic Cancer May Help - Health Care Today
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.12 Articles
12 Articles
Il Tempo
Rome, 11 Sep. (Adnkronos Salute) - The Italian Association of Medical Oncology (Aiom) asks Revolution Medicines "to start the program of compassionate use for Daraxonrasib, thus making available free of charge the drug, before regulatory approval, in patients with metastatic pancreas cancer already treated with chemotherapy."
Drug approved by FDA for pancreatic cancer may help - Health Care Today
Share on PinterestA drug approved by FDA for pancreatic cancer may help treat lung cancer, too. selimaksan/ Getty Images An experimental treatment may offer a new option for people with advanced lung cancer linked to RAS mutations. The Food and Drug Administration (FDA) recently approved daraxonrasib (Rasonque) for certain people with metastatic pancreatic cancer, but [...]
FDA Authorizes Daraxonrasib for Metastatic Pancreatic Cancer After Positive Phase 3 Trial Results
As reported on World Pharma News, the U.S. Food and Drug Administration has granted approval to daraxonrasib, an oral RAS-targeting therapy, for adults with metastatic pancreatic adenocarcinoma who have previously received systemic treatment or are not suitable candidates for multiagent chemotherapy. The regulatory decision was largely supported by data from the phase 3 RASolute 302 […]
The Italian Association of Medical Oncology (Aiom) asks Revolution Medicines "to start the program of compassionate use for Daraxonrasib, thus making available free of charge the drug, before regulatory approval, in patients with metastatic pancreatic cancer already treated with chemotherapy." It is "a targeted therapy that, although it has produced results only in [...]
Rec News | Lontani dal mainstream
notizie.it(Adnkronos) L'Associazione italiana di oncologia medica (Aiom) asks Revolution Medicines to start the program of compassionate use for Daraxonrasib, thus making available free of charge the drug, before regulatory approval, in patients with metastatic pancreas cancer already treated with chemotherapy. It is a targeted therapy that, although having produced so far results only in [...] L'articolo Tumori, Aiom: "Starting compassionate use program …
Coverage Details
Bias Distribution
- 100% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
